(193 days)
Prescription: The Axiostat Gauze is intended for use as a temporary external dressing to control moderate to severe bleeding and manage external abrasions, lacerations.
Over-the-Counter: The Axiostat Gauze is indicated for the local management of bleeding wounds such as minor cuts, lacerations, and abrasions.
The Axiostat Gauze is a single-use, non-absorbable non-woven hemostatic gauze. It is made of non-woven fabric derived from chitosan, which is a natural polymer. Chitosan is known for its mucoadhesive and hemostatic properties. When applied directly to a wound the dressing controls bleeding and can be removed after the clotting has occurred. The dressing should be removed within 24 hours. The dressing is not intended to be implanted. The Axiostat Gauze is individually packed in a moisture proof packaging and terminally sterilized by gamma radiation to a sterility assurance level (SAL) of 10-6.
Here's an analysis of the acceptance criteria and study information for the Axiostat Gauze, based on the provided text:
1. Table of Acceptance Criteria and Reported Device Performance
| S.No | Test | Acceptance Criteria | Reported Device Performance |
|---|---|---|---|
| 1. | Appearance | Color - Cream/off yellow, No loose fibers, no holes/tears, no dust particles | Product visually checked before packing to ensure it meets the set criteria (implies compliance). |
| 2. | Moisture content | Not more than 35% in the test device | Moisture content results in the stability study are less than 35% at all time points. |
| 3. | Absorbency | Not less than 15 times of product weight | Axiostat Gauze absorbs fluids up to 15 times its own weight (implies meeting or exceeding). |
| 4. | pH | 5 to 7 | A mildly acidic to neutral pH is required for adhesion and hemostatic activity (implies compliance with this range for optimal function). |
| 5. | Tensile strength | Dry - >5N/25mmWet - >1N/25mm | The adhesive strength to the tissue/application site is less than the set acceptance criteria for Tensile strength, preventing product breakage during removal (implies compliance). |
| 6. | Integrity (dispersion test) | Product remain intact | The outcome demonstrates the integrity of Axiostat Gauze on the application site (implies compliance). |
| 7. | In-vitro clot assessment: Blood clotting time | Not more than 60% average clotting of control (recalcified blood) | Faster clotting compared to recalcified blood (control) (implies meeting or exceeding, aiming for higher efficacy). |
| 7. | In-vitro clot assessment: Blood clotting index | Not more than 5% Blood clotting Index | Lower BCI for better clotting (implies meeting or exceeding, aiming for higher efficacy). |
| - | Biocompatibility (Cytotoxicity) | Non-cytotoxic | Non-cytotoxic |
| - | Biocompatibility (Skin Sensitization) | Non-toxic | Non-toxic |
| - | Biocompatibility (Acute Dermal Irritation) | Non-toxic | Non-toxic |
| - | Biocompatibility (Acute Systemic Toxicity) | Non-toxic | Non-toxic |
| - | Biocompatibility (Hemolysis) | Non-hemolytic | Non-hemolytic |
| - | Biocompatibility (Bacterial Endotoxin Test) | Complies | Complies |
| - | Heavy metal testing | Met USP-232 limits | Met USP-232 limits |
| - | Residual solvent testing (IPA & Acetic Acid) | Within safety limit | Within the safety limit |
| - | Animal Study (Hemostasis) | Hemostasis in under 5 minutes; no rebleeding for 2 hours | Successfully achieved hemostasis in under 5 minutes in all test animals; no rebleeding observed in any animals during the observation period of two hours. |
| - | Shelf Life (Package Integrity) | Validated for 30 months | Confirmed by real time and accelerated stability studies. |
2. Sample Size Used for the Test Set and Data Provenance
- Animal Studies: The text states "all test animals" but does not specify the exact number.
- Other tests (Biocompatibility, Bench, Heavy Metal, Residual Solvent, Sterilization, Shelf-life): The text does not provide specific sample sizes for these tests.
- Data Provenance: The animal study followed an existing methodology ("Safety Evaluation of New Hemostatic Agents... in Swine; Kheirabadi, et al., J Trauma. 2010 Feb;68(2):269-78."), indicating a prospective, controlled experimental design in a swine model. The other tests are non-clinical, laboratory-based tests. The country of origin for the data is not specified, other than the manufacturer being Advamedica Inc. in the USA.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications
- The document does not mention using experts to establish ground truth for any of the performance tests. The ground truth for these tests is based on established scientific standards, protocols, and measurements (e.g., ISO standards, USP monographs, in-vitro assays, animal study observations).
4. Adjudication Method for the Test Set
- The document does not describe an adjudication method for the test set. Given the types of tests (biocompatibility, bench, animal study observations), adjudication by experts, as might be seen in imaging studies, is not applicable or mentioned.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done
- No, an MRMC comparative effectiveness study was not done. This type of study typically involves human readers interpreting diagnostic images or information, often with and without AI assistance, to assess performance and clinical utility. The Axiostat Gauze is a physical medical device (hemostatic gauze), not a diagnostic AI tool, so an MRMC study is not relevant.
6. If a Standalone (Algorithm Only Without Human-in-the-Loop Performance) Was Done
- This question is not applicable as the Axiostat Gauze is a physical medical device and not an algorithm or AI system.
7. The Type of Ground Truth Used
- For Biocompatibility, Heavy Metal, and Residual Solvent Tests: The ground truth is established by regulatory standards and recognized scientific methodologies (e.g., ISO 10993 series, USP 161, USP 232, USP 30 <467>).
- For Bench Performance Tests: The ground truth is based on defined physical and chemical properties measured against specified acceptance criteria (e.g., color, moisture content, absorbency, pH, tensile strength, integrity, in-vitro clotting parameters).
- For Animal Studies: The ground truth is physiological observation and measurement of hemostasis (cessation of bleeding) and the absence of rebleeding in a live animal model, following a published experimental protocol.
8. The Sample Size for the Training Set
- This question is not applicable as the Axiostat Gauze is a physical medical device and not a machine learning model that requires a training set.
9. How the Ground Truth for the Training Set Was Established
- This question is not applicable for the same reason as above.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
April 7, 2023
Advamedica Inc. % Alan Donald President Matrix Medical Consulting, Inc. 8880 Rio San Diego Drive. Suite 800 San Diego, California 92108
Re: K222909 Trade/Device Name: Axiostat Gauze Regulatory Class: Unclassified Product Code: FRO Dated: March 2, 2023 Received: March 2, 2023
Dear Alan Donald:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal
{1}------------------------------------------------
statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Julie A. Morabito -S
Julie Morabito, Ph.D. Assistant Director DHT4B: Division of Infection Control and Plastic Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Ouality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known)
Device Name Axiostat Gauze
Indications for Use (Describe)
Prescription:
The Axiostat Gauze is intended for use as a temporary external dressing to control moderate to severe bleeding and manage external abrasions, lacerations.
Over-the-Counter:
The Axiostat Gauze is indicated for the local management of bleeding wounds such as minor cuts, lacerations, and abrasions.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ------------------------------------------------- | -- |
X Prescription Use (Part 21 CFR 801 Subpart D)
X Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
Image /page/3/Picture/1 description: The image shows the logo for Advamedica. The logo consists of a stylized teal-colored icon resembling two overlapping triangles, followed by the word "ADVAMEDICA" in gray, sans-serif font. The icon is positioned to the left of the text, creating a balanced and professional visual identity.
510(k) SUMMARY
AXIOSTAT GAUZE
1. ADMINISTRATIVE INFORMATION
- Date of preparation: 4/7/2023 a.
| b. | Submitter: | Advamedica Inc.Harvard Square, 1 Mifflin Place,Suite 400, Cambridge,Massachusetts 02138, USAPhone: +1 973-718-7575Fax: +1 888-584-8237 |
|---|---|---|
| c. | Contact Person: | Mr. Leo Mavely,President, Advamedica Inc.Email: office@advamedica.comWeb: www.advamedica.com |
| d. | Prepared By: | Mr. Leo Mavely, President |
- Advamedica, Inc.
DEVICE NAME AND CLASSIFICATION 2.
| a. | Trade/ Proprietary Name : | Axiostat Gauze |
|---|---|---|
| b. | Common Name : | Wound dressing |
| c. | Classification Name : | Dressing, Wound, Drug |
| d. | Regulatory Class : | Unclassified |
| e. | Product code : | FRO |
| f. | Classification Panel : | General and Plastic Surgery |
{4}------------------------------------------------
Image /page/4/Picture/1 description: The image shows the logo for Advamedica. The logo consists of a stylized teal-colored symbol resembling a mountain range or interconnected triangles on the left. To the right of the symbol is the company name "ADVAMEDICA" in a gray, sans-serif font. The overall design is clean and modern.
IDENTIFICATION OF PREDICATE DEVICE 3.
| Parameters | Predicate Device | Proposed Device |
|---|---|---|
| 510(k) Number | K143462 | K222909 |
| Trade/ProprietaryName | Anscare ChitoClot Gauze | Axiostat Gauze |
| Manufacturer | BenQ Materials Corporation | Advamedica Inc. |
| Regulatory Class | Unclassified | Unclassified |
| Classification Name | Dressing, Wound, Drug | Dressing, Wound, Drug |
| Product Code | FRO | FRO |
| Panel | General & Plastic Surgery | General & Plastic Surgery |
Table. 1: Predicate Device Details
DEVICE DESCRIPTION 4.
The Axiostat Gauze is a single-use, non-absorbable non-woven hemostatic gauze. It is made of non-woven fabric derived from chitosan, which is a naturalpolymer. Chitosan is known for its mucoadhesiveand hemostatic properties.
When applied directly to a wound the dressing controls bleeding and can be removed after the clotting has occurred. The dressing should be removed within 24 hours. The dressing is not intended to be implanted.
The Axiostat Gauze is individually packed in a moisture proof packaging and terminally sterilized by gamma radiation to a sterility assurance level (SAL) of 10-6.
{5}------------------------------------------------
Image /page/5/Picture/1 description: The image shows the logo for Advamedica. The logo consists of a stylized letter "M" in teal, followed by the word "ADVAMEDICA" in gray. The "M" is made up of three connected lines that form a mountain-like shape.
Image /page/5/Picture/2 description: In the image, two hands wearing white gloves are holding several sheets of white paper. The hands are positioned on either side of the paper, with one hand holding the top sheets and the other holding the bottom sheets. The paper appears to be thin and delicate, and the hands are holding it carefully to avoid tearing it. There is a stack of paper below the sheets that are being held.
Fig 1: Axiostat Gauze
The Axiostat Gauze can be cut to any size within the permissible size limit and packed in three different folds,
- a) Folded gauze in the form of single ply, 2-ply, or 4-ply folds,
- b) Z-folded gauze in the form of zig-zag pattern
- c) Rolled gauze in the form of a roll.
Axiostat Gauze is currently available in the following sizes.
Folded single ply, 2 ply, 4 ply
2"x2" (5 cm x 5cm) 3"x3" (7.5cmx 7.5cm) 4"x4" (10cm x10cm) 6"x6" (15cm x15cm) 8"x8" (20cm x 20cm) 12"x12" (30cm x30cm) 16"x16" (40cm x 40cm)
Z folded
3" x 59" (7.6cm x 150cm) 3" x 78" (7.6cm x 200cm) 3" x 98" (7.6cm x 250cm)
{6}------------------------------------------------
Image /page/6/Picture/1 description: The image shows the logo for Advamedica. The logo consists of a stylized letter "M" in teal, followed by the word "ADVAMEDICA" in gray. The "M" is made up of three connected lines that form a peak in the center. The text is in a sans-serif font and is aligned to the right of the "M" symbol.
- 3" x 118" (7.6cm x 300cm) 3" x 137" (7.6cm x 350 cm) 3" x 156" (7.6cm x 400cm)
Rolled
3" x 19" (7.6cm x 50cm)
3"x 39" (7.6cm x 100cm)
3" x 59" (7.6cm x 150cm)
3" x 78" (7.6cm x 200cm)
3" x 98" (7.6cm x 250cm)
3" x 118" (7.6cm x 300cm)
INDICATIONS FOR USE 5.
5.1 Prescription Use:
The Axiostat Gauze is intended for use as a temporary external dressing to control moderate to severe bleeding and manage external abrasions, lacerations.
5.2 Over the Counter Use:
The Axiostat Gauze is indicated for the local management of bleeding wounds such as minor cuts, lacerations, and abrasions.
COMPARISON OF TECHNOLOGICAL CHARACTERISTICS OF SUBJECT 6. AND PREDICATE DEVICES
The Axiostat Gauze is technologically similar to Anscare ChitoClot Gauze. The subject device has the following similarities to the predicate device:
- Indication for use .
- Mechanism of action .
- Active material .
- Sterility .
- Biocompatibility
- Packaging .
- Contact duration and anatomical site .
{7}------------------------------------------------
Image /page/7/Picture/1 description: The image shows the logo for Advamedica. The logo consists of a stylized teal-colored symbol resembling a stylized letter 'M' or a mountain range. To the right of the symbol, the word "ADVAMEDICA" is written in a dark gray, sans-serif font. The logo appears to be for a medical or healthcare-related company.
Table 2: Comparison of technological characteristics of the Predicate Device and Subject Device
| Parameters | Predicate Device | Subject Device | Notes |
|---|---|---|---|
| 510(k) Number | K143462 | K222909 | -- |
| Trade/ProprietaryName | AnscareGauze | ChitoClotAxiostat Gauze | -- |
| Manufacturer | BenQMaterialsCorporation | Advamedica Inc. | -- |
| Regulatory Class | Unclassified | Unclassified | Same |
| Product Code | FRO | FRO | Same |
| Indication for use(prescription use) | For use as a temporaryexternal dressing tocontrol moderate tosevere bleeding andmanage externalabrasions, lacerations. | The Axiostat Gauze isintended for use as atemporary externaldressing to controlmoderate to severebleeding and manageexternal abrasions,lacerations. | Same |
| Indication for use(OTC) | To control bleeding oflacerations, minor cuts,and abrasions. | To control bleeding oflacerations, cuts, andabrasions. | Same |
| Anatomical Site | External Wounds | External Wounds | Same |
| Physicalcomposition | Soft absorbent, non-woven gauze | Soft absorbent, non-woven gauze | Same |
| Material | Chitosan | Chitosan | Same |
| Indicatedforcontrolofbleeding? | Yes | Yes | Same |
| Contact Duration | Up to 24 hours | Up to 24 hours | Same |
| MechanismofAction | When applied directly on a wound with firm pressure, the AnsCare ChitoClot Gauze will turn into a gel-like condition to absorb the blood and seal the wound. | When applied on the bleeding site with firm pressure, the Axiostat Gauze acts as a mechanical barrier against bleeding. | Similar |
| Shelf life | 36 months | 30 months | Similar |
| Biocompatibility(ISO 10993) | Yes | Yes | Same |
| Sterility | Gamma-Sterilized | Gamma-Sterilized | Same |
| Packaging | Foil-Pouch | Foil-Pouch | Same |
| Sizes | Various | Various | Same |
{8}------------------------------------------------
Image /page/8/Picture/1 description: The image shows the logo for Advamedica. The logo consists of a stylized teal-colored symbol on the left, resembling a mountain range or an abstract letter 'A'. To the right of the symbol is the word "ADVAMEDICA" in gray, with each letter clearly visible and evenly spaced. The overall design is clean and professional.
7. PERFORMANCE DATA
{9}------------------------------------------------
Image /page/9/Picture/1 description: The image shows the logo for Advamedica. The logo consists of a stylized, teal-colored symbol resembling two overlapping triangles, followed by the word "ADVAMEDICA" in gray, sans-serif font. The logo is simple and modern, with a focus on the company name.
The Subject Device has been evaluated through a series of nonclinical studies to determine whether Axiostat Gauze meets the acceptance criteria for its intended applications. These tests are summarized below.
7.1. Biocompatibility testing
The Biocompatibility tests have been performed as per the requirements of ISO 10993-1:2009, under the section "Surface devices used on Breached or compromised surface" with limited contact duration (≤ 24 hrs)"
The following tests have been carried out as per these requirements-
| S.No. | Biocompatibility test | Standardfollowed | Outcome |
|---|---|---|---|
| 1. | Cytotoxicity | ISO 10993-5 | Non-cytotoxic |
| 2. | Skin Sensitization | ISO 10993-10 | Non-toxic |
| 3. | Acute Dermal Irritation | ISO 10993-10 | Non-toxic |
| 4. | Acute Systemic Toxicity | ISO 10993-11 | Non-toxic |
| 5. | Hemolysis | ISO 10993-4 | Non-hemolytic |
| 6. | Bacterial Endotoxin Test | USP 161 | Complies |
Table 3: Biocompatibility test details
7.2. Heavy metal testing
The Subject Device was tested for the heavy metal contamination in the finished sterilized product, which met USP-232 limits ((232) ELEMENTAL IMPURITIES-LIMITS).
7.3. Residual solvent testing
The subject device was tested for the presence of residual solvents - isopropyl alcohol (IPA) and acetic acid in the device as per USP 30 <467>. This test is intended to assess the performance and safety of the device. It was found that the Axiostat Gauze is entirely composed of chitosan acetate and the level of residual isopropyl alcohol and acetic acid in the Axiostat Gauze are within the safety limit.
7.4. Bench performance testing
{10}------------------------------------------------
Image /page/10/Picture/1 description: The image features the logo for Advamedica. The logo consists of a stylized letter "M" in teal, positioned to the left of the company name, "ADVAMEDICA," which is written in gray, sans-serif font. The overall design is clean and modern.
The Subject Device is evaluated through following bench tests.
Table 4: Bench performance testing
| S.No | Test | Acceptance Criteria | Reference/Justification |
|---|---|---|---|
| 1. | Appearance | Color - Cream/offyellowForeignparticle/undesiredphysical appearancesNo loose fibers, noholes/tears, no dustparticles | The product is visually checked beforepacking to ensure it meets the setcriteria. |
| 2. | Moisturecontent | Not more than 35% inthe test device | Moisture from the manufacturingprocess may be retained in the finishedproduct.Moisture content results in the stabilitystudy are less than 35% at all timepoints, with no change in the desiredproperties. |
| 3. | Absorbency | Not less than 15 timesof product weight | Traditional laparotomy sponges absorb5 times their weight in fluid. AxiostatGauze is an advanced hemostat thatabsorbs fluids up to 15 times its ownweight. |
| 4. | pH | 5 to 7 | A mildly acidic to neutral pH is requiredfor adhesion and hemostatic activity. |
| 5. | Tensilestrength | Dry - >5N/25mmWet - >1N/25mm | The adhesive strength tothetissue/application site is less than the setacceptance criteria for Tensile strength.This prevents the product from breakingduring removal from the applicationsite. |
| 6. | Integrity(dispersiontest) | Product remain intact | The outcome demonstrates the integrityof Axiostat Gauze on the applicationsite.BS EN 13726-1:2002 |
| 7. | In-vitro clotassessment | Blood clotting time:Clotting time withAxiostat Gauze shouldbe not more than 60%average clotting ofcontrol(recalcifiedblood)Blood clotting index:The BCI of AxiostatGauze should be notmore than 5% Bloodclotting Index | Blood clotting time: The faster theblood clots compared to recalcifiedblood (control), the better thehemostatic efficacy of Axiostat Gauze.Blood clotting index: represents thepercentage of non-coagulated blood inthe Axiostat Gauze, and the lower theBCI, the better the clotting. |
{11}------------------------------------------------
Image /page/11/Picture/1 description: The image shows the logo for Advamedica. The logo consists of a teal-colored abstract symbol on the left, resembling a stylized letter 'M' or a mountain range. To the right of the symbol is the word "ADVAMEDICA" in a gray, sans-serif font. The overall design is clean and modern.
7.5. Animal studies
Animal testing was conducted to evaluate the hemostatic efficiency of the Axiostat Gauze in extremity arterial hemorrhage model in swine at an external laboratory as necessitated by FDA standards.
Advamedica has performed the animal testing as described in-
"Safety Evaluation of New Hemostatic Agents, Smectite Granules, and Kaolin-Coated Gauze in a Vascular Injury Wound Model in Swine; Kheirabadi, et al., J Trauma. 2010 Feb;68(2):269-78."
The Subject Device successfully achieved hemostasis in under 5 minutes in all test animals and no rebleeding was observed in any animals during the observation period of two hours.
8. Sterilization and Shelf life
The Axiostat Gauze is packaged in moisture proof packs. The product is terminally sterilized using gamma radiation to a sterility assurance level (SAL) of 106. The dose of gamma radiation has been optimized and validated per ISO 11137-2.
{12}------------------------------------------------
Image /page/12/Picture/1 description: The image shows the logo for Advamedica. The logo consists of a stylized letter "M" in teal, followed by the word "ADVAMEDICA" in gray. The font is sans-serif and the logo is simple and modern.
Following gamma sterilization, the package integrity was subjected to sterile barrier testing to validate a shelf life of 30 months. The stability and effectiveness of packaging of the sterilized product during the shelf-life was confirmed by real time (to support 30 months shelf life) and accelerated stability studies.
The following tests were performed periodically in the validation of 30 months shelf life.
{13}------------------------------------------------
Image /page/13/Picture/1 description: The image shows the logo for Advamedica. The logo consists of a stylized teal-colored symbol on the left, resembling a stylized letter "M" or a mountain range. To the right of the symbol is the word "ADVAMEDICA" in a gray, sans-serif font. The overall design is clean and modern, suggesting a company in the medical or technology field.
Product tests to validate the shelf life are as mentioned below -
- Appearance visual check .
- Moisture content as per ASTM E1868-10 .
- Absorbency as per BS EN 13726-1:2002 .
- pH as per BS EN 13726-1:2002 .
- Dispersion or integrity test as per BS EN 13726-1:2002 .
- Tensile strength test as per BS EN 29073-3:1992 and ISO 9073-18 .
Package tests to validate the shelf life are as mentioned below -
- Seal strength test as per ASTM F88 .
- Dye penetration test as per ASTM F3039-15 .
- . Sterility test as per US Pharmacopeia <71>
- Bacterial Endotoxin Test as per US Pharmacopeia <161> .
9. Conclusion
The Axiostat Gauze is substantially equivalent to the predicate device with respect to the risk-based classification, product code as defined by US FDA, intended use & indications for use, application site, physical composition, design material, method of sterilization, and biocompatibility. The non-clinical testing data provided supports the safety and performance of the device for the claimed Indications for Use statement. Hence, the minor differences between the subject devices and the predicates do not raise any new device safety or performance issues.
N/A